Human IL-28A/IFN-lambda 2 Antibody Summary
Accession # Q8IZJ0
This antibody functions as an ELISA detection antibody when paired with Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15872).
This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Human IL-28A/IFN-lambda 2 DuoSet ELISA Kit (Catalog # DY1587) for convenient development of a sandwich ELISA.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IL‑28A/IFN‑ lambda 2 in Human PBMCs. IL-28A/IFN-lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Human IL‑28A/IFN‑ lambda 2 ELISA Standard Curve. Recombinant Human IL-28A/IFN-lambda 2 protein was serially diluted 2-fold and captured by Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).
IL‑28A/IFN‑ lambda 2 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑28A/IFN‑ lambda 2 Antibody. Recombinant Human IL-28A/ IFN-lambda 2 (Catalog # 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND50 is typically 0.3-1.5 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-28A/IFN-lambda 2
IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including anti-viral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.
Citations for Human IL-28A/IFN-lambda 2 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway.
Cell. Signal., 2012;24(9):1734-42.
Sample Types: Cell Lysates
Applications: Western Blot
Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects.
Authors: Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M
Br. J. Cancer, 2011;105(9):1302-12.
Sample Types: Cell Culture Supernates
Applications: Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human IL-28A/IFN-lambda 2 Antibody
There are currently no reviews for this product. Be the first to review Human IL-28A/IFN-lambda 2 Antibody and earn rewards!
Have you used Human IL-28A/IFN-lambda 2 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image